Pharmacological modulation of Cxs‐based channels, particularly Cx43, has emerged as a promising therapeutic approach in neurodegenerative diseases and several compounds targeting Cx43 have shown preclinical efficacy. Here, GJA1 is linked to neurodegenerative disease.